$PRME
Prime Medicine, Inc. Stock $prme

$prme Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035893 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$209.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.10M	$12.60M
YoY Change	34.42%	18.21%
% of Gross Profit
Research & Development	$40.34M	$43.07M
YoY Change	-1.54%	24.48%
% of Gross Profit
Depreciation & Amortization	$1.558M	$1.538M
YoY Change	26.05%	37.57%
% of Gross Profit
Operating Expenses	$54.44M	$55.67M
YoY Change	5.79%	23.01%
Operating Profit	-$54.23M	-$55.67M
YoY Change	5.39%	23.01%
Interest Expense	$1.797M	$172.0K
YoY Change	-213.73%	-33.85%
% of Operating Profit
Other Income/Expense, Net	$1.714M	$211.0K
YoY Change	166.56%	-92.73%
Pretax Income	-$52.52M	-$55.46M
YoY Change	3.34%	30.96%
Income Tax	$0.00	-$134.0K
% Of Pretax Income
Net Earnings	-$52.52M	-$55.33M
YoY Change	3.57%	30.53%
Net Earnings / Revenue	-25128.23%
Basic Earnings Per Share	-$0.44	-$0.46
Diluted Earnings Per Share	-$0.44	-$0.46
COMMON SHARES
Basic Shares Outstanding	120.0M shares	120.0M shares
Diluted Shares Outstanding	119.8M shares	119.2M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$175.5M	$162.9M
YoY Change	6.19%	-21.55%
Cash & Equivalents	$118.0M	$55.60M
Short-Term Investments	$57.55M	$107.3M
Other Short-Term Assets	$9.538M	$3.736M
YoY Change	-50.32%	-65.64%
Inventory
Prepaid Expenses	$6.006M	$4.199M
Receivables	$55.00M
Other Receivables	$0.00
Total Short-Term Assets	$246.1M	$170.8M
YoY Change	33.35%	-21.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.29M	$23.81M
YoY Change	5.7%	15.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$86.71M	$88.90M
YoY Change	58.77%	42.53%
TOTAL ASSETS
Total Short-Term Assets	$246.1M	$170.8M
Total Long-Term Assets	$86.71M	$88.90M
Total Assets	$332.8M	$259.7M
YoY Change	39.16%	-7.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.429M	$4.638M
YoY Change	-61.56%	-15.52%
Accrued Expenses	$18.68M	$10.90M
YoY Change	33.24%	-49.87%
Deferred Revenue	$9.280M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$37.88M	$20.75M
YoY Change	-3.78%	-27.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$105.4M	$42.37M
YoY Change	1717.29%	255.04%
Total Long-Term Liabilities	$105.4M	$42.37M
YoY Change	1717.29%	255.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.88M	$20.75M
Total Long-Term Liabilities	$105.4M	$42.37M
Total Liabilities	$143.3M	$63.12M
YoY Change	217.08%	54.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$644.9M	-$592.4M
YoY Change	51.49%	57.97%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$189.5M	$196.6M
YoY Change
Total Liabilities & Shareholders Equity	$332.8M	$259.7M
YoY Change	39.16%	-7.53%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$52.52M	-$55.33M
YoY Change	3.57%	30.53%
Depreciation, Depletion And Amortization	$1.558M	$1.538M
YoY Change	26.05%	37.57%
Cash From Operating Activities	-$25.91M	-$45.49M
YoY Change	-33.85%	11.44%
INVESTING ACTIVITIES
Capital Expenditures	$1.277M	$1.902M
YoY Change	-55.97%	-3.74%
Acquisitions
YoY Change
Other Investing Activities	$51.62M	$8.796M
YoY Change	-248.08%	-70.52%
Cash From Investing Activities	$50.34M	$6.894M
YoY Change	-233.29%	-75.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.51M	35.00K
YoY Change	11935.31%	-53.33%
NET CHANGE
Cash From Operating Activities	-25.91M	-45.49M
Cash From Investing Activities	50.34M	6.894M
Cash From Financing Activities	38.51M	35.00K
Net Change In Cash	62.94M	-38.56M
YoY Change	-182.15%	199.28%
FREE CASH FLOW
Cash From Operating Activities	-$25.91M	-$45.49M
Capital Expenditures	$1.277M	$1.902M
Free Cash Flow	-$27.19M	-$47.39M
YoY Change	-35.37%	10.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34599000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	55672000	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120030813	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001894562
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Security12b Title Security12bTitle	Common stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	PRME
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120030813	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55600000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41574000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4199000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19057000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3736000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2254000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	170803000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	142976000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23812000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	51594000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13941000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	13496000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	779000	usd
CY2024Q2	us-gaap	Assets Assets	259705000	usd
CY2023Q4	us-gaap	Assets Assets	193851000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4638000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19537000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10895000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2024Q2	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	0	usd
CY2023Q4	prme	Accrued Settlement Payment Current AccruedSettlementPaymentCurrent	13500000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36367000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4357000	usd
CY2024Q2	prme	Research And Development Funding Liability Noncurrent ResearchAndDevelopmentFundingLiabilityNoncurrent	6000000	usd
CY2023Q4	prme	Research And Development Funding Liability Noncurrent ResearchAndDevelopmentFundingLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Liabilities Liabilities	63116000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	60780000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120030813	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	789076000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	624414000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-592418000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491330000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	196589000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259705000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193851000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43071000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80845000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12601000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10658000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23759000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	45257000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-55672000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-45257000	usd
CY2024Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1486000	usd
CY2023Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1964000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	611000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	635000	usd
CY2024Q2	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	-1925000	usd
CY2023Q2	prme	Change In Fair Value Of Short Term Investment ChangeInFairValueOfShortTermInvestment	263000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	211000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2903000	usd
CY2024Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-55461000	usd
CY2023Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-42354000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-134000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55327000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55327000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-101088000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-101088000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119188866	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119188866	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111827522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111827522	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-55327000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-42385000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	24000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-63000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55303000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42448000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	133071000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	132055000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18800000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	436000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5209000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-80000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-45761000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	243766000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8091000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	24000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-55327000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	196589000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	316270000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1681000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	179000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39397000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	278801000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3583000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-63000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-42385000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	240102000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-81782000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	13300000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5264000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7917000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6304000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2853000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2170000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-759000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1438000	usd
	prme	Accretion Amortization Of Discounts And Premiums Short Term Investments AccretionAmortizationOfDiscountsAndPremiumsShortTermInvestments	2079000	usd
	prme	Accretion Amortization Of Discounts And Premiums Short Term Investments AccretionAmortizationOfDiscountsAndPremiumsShortTermInvestments	1403000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-171000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2519000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5299000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9230000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1104000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3939000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3438000	usd
	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	-13500000	usd
	prme	Increase Decrease In Accrued Settlement Payment IncreaseDecreaseInAccruedSettlementPayment	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5672000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6569000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-113198000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82382000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	110000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	65000000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	135912000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	45659000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4226000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3975000	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	0	usd
	prme	Payments For Security Deposits PaymentsForSecurityDeposits	170000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30138000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15196000	usd
	prme	Proceeds From Issuance Follow On Offering ProceedsFromIssuanceFollowOnOffering	132055000	usd
	prme	Proceeds From Issuance Follow On Offering ProceedsFromIssuanceFollowOnOffering	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18800000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	prme	Proceeds From Research And Development Funding Liability ProceedsFromResearchAndDevelopmentFundingLiability	6000000	usd
	prme	Proceeds From Research And Development Funding Liability ProceedsFromResearchAndDevelopmentFundingLiability	0	usd
	prme	Proceeds From Espp Offerings ProceedsFromESPPOfferings	436000	usd
	prme	Proceeds From Espp Offerings ProceedsFromESPPOfferings	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	71000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	143000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	157362000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14026000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-67043000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55070000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201116000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69096000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134073000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69096000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134073000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	13496000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55600000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120577000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44935000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3265000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	355000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	712000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-592400000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	162900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to the valuation of the Company’s common stock and stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></div>
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	162374000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	104300000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	102645000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	70000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	102575000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	74654000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	74639000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	102575000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	74639000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34149000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30143000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10337000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7484000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23812000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22659000	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1538000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1118000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2853000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2170000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4986000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8270000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3836000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2273000	usd
CY2024Q2	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1101000	usd
CY2023Q4	prme	Accrued Lab Related Supplies And Services Current AccruedLabRelatedSuppliesAndServicesCurrent	1962000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	972000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1605000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10895000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14110000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3176000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18584000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21339000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20812000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	20853000	usd
CY2024Q2	prme	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	118079000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	202843000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	129850000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	31410000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	41583000	usd
CY2024Q2	prme	Common Stock Par Or Stated Value Per Share Under Amendment CommonStockParOrStatedValuePerShareUnderAmendment	0.0001
CY2024Q2	prme	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7641863	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4268210	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.16
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	19203	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	268635	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.34
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11622235	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.17
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3682315	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.44
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11622235	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.17
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8091000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3583000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5264000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55327000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55327000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42385000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-42385000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-101088000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-101088000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-81782000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-81782000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119188866	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119188866	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90467298	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90467298	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111827522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111827522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89769970	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89769970	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3200005	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15737320	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13466614	shares

Files In Submission

Name	View Source	Status
0001628280-24-035893-index-headers.html	Edgar Link	pending
0001628280-24-035893-index.html	Edgar Link	pending
0001628280-24-035893.txt	Edgar Link	pending
0001628280-24-035893-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prme-20240630.htm	Edgar Link	pending
prme-20240630.xsd	Edgar Link	pending
q22024ex101-amendeddirecto.htm	Edgar Link	pending
q22024ex311.htm	Edgar Link	pending
q22024ex312.htm	Edgar Link	pending
q22024ex321.htm	Edgar Link	pending
q22024ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
prme-20240630_def.xml	Edgar Link	unprocessable
prme-20240630_lab.xml	Edgar Link	unprocessable
prme-20240630_pre.xml	Edgar Link	unprocessable
prme-20240630_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prme-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRME
Prime Medicine, Inc. Stock $prme

2024 Q3 Form 10-Q Financial Statement

#000162828024035893 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME Prime Medicine, Inc. Stock $prme

2024 Q3 Form 10-Q Financial Statement

#000162828024035893 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRME
Prime Medicine, Inc. Stock $prme